Integral Health Asset Management’s AstraZeneca AZN Stock Holding History

Integral Health Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-250,000	Closed	-$49.3M	–	93
2026 Q1	$49.3M	Buy	250,000 +75,000	+43%	+$14.5M	2.36%	14
2025 Q4	$32.2M	Buy	175,000 +25,000	+17%	+$4.38M	1.6%	16
2025 Q3	$23M	Buy	150,000 +50,000	+50%	+$7.57M	1.56%	17
2025 Q2	$14M	Buy	+100,000	New	+$14M	1.28%	28
2025 Q1	–	Sell	-112,500	Closed	-$14.7M	–	84
2024 Q4	$14.7M	Buy	+112,500	New	+$15.8M	1.26%	28
2023 Q1	–	Sell	-70,000	Closed	-$9.49M	–	72
2022 Q4	$9.49M	Buy	+70,000	New	+$8.78M	1.99%	21
2022 Q3	–	Sell	-117,415	Closed	-$15.5M	–	68
2022 Q2	$15.5M	Buy	117,415 +67,415	+135%	+$8.85M	3.19%	7
2022 Q1	$6.63M	Hold	50,000	–	–	1.73%	20
2021 Q4	$5.83M	Buy	+50,000	New	+$5.88M	1.61%	26
2020 Q3	–	Sell	-62,500	Closed	-$6.61M	–	77
2020 Q2	$6.61M	Sell	62,500 -32,500	-34%	-$3.36M	1.98%	22
2020 Q1	$8.48M	Buy	+95,000	New	+$8.94M	3.74%	7

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Integral Health Asset Management's AZN Position: Q2 2026 in Review

Integral Health Asset Management sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 250,000 shares — an estimated $49.3M sold.

Integral Health Asset Management first reported a position in AZN in Q1 2020 and held it in 11 quarters. The position peaked at $49.3M in Q1 2026. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Integral Health Asset Management reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Integral Health Asset Management sold 250,000 AstraZeneca shares in Q2 2026, an estimated $49.3M.
Integral Health Asset Management first reported a position in AstraZeneca in Q1 2020 and held it in 11 quarters.
Integral Health Asset Management's AstraZeneca position peaked at $49.3M in Q1 2026.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.